The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
|Articles|July 9, 2014
- Hematologic Malignancies
- Volume 1
- Issue 1
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
Author(s)Timothy S. Pardee, MD
Timothy S. Pardee, MD, discusses comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).
Advertisement
Timothy S. Pardee, MD, assistant professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, discusses comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).
Read about new treatments for AML > >
Articles in this issue
over 12 years ago
In the Pipeline: Potential New Treatments for AMLover 12 years ago
Epidemiology in B-Cell Malignanciesover 12 years ago
Pathogenesis of Follicular Lymphomaover 12 years ago
Resistance to Ibrutinibover 12 years ago
IPI-145 and ABT-199 for Lymphoid Malignanciesover 12 years ago
BCL-2 Inhibitor Combo May Offer Remissions in CLLAdvertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The FDA granted orphan drug designation to Cardiff Oncology’s PLK1 inhibitor onvansertib for relapsed or refractory CMML after early phase 1 activity.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5